US2010227806A1PendingUtilityA1

Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment

30
Assignee: GIOVANNI TULIPANOPriority: Mar 10, 2006Filed: Mar 9, 2007Published: Sep 9, 2010
Est. expiryMar 10, 2026(expired)· nominal 20-yr term from priority
Inventors:Tulipano Giovanni
A61P 5/44A61P 5/00A61P 3/00A61K 38/25A61P 19/08
30
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, specifically [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2 , to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.

Claims

exact text as granted — not AI-modified
1 . A method to ameliorate the catabolic effects of excess glucocorticoids in an individual in need of such treatment comprising administering to said individual a therapeutically effective amount of a ghrelin agonist. 
   
   
       2 . A method according to  claim 1 , in which said ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2  (SEQ ID NO:2). 
   
   
       3 . A method according to  claim 1  wherein said excess glucocorticoids are the result of a disease or a condition. 
   
   
       4 . A method according to  claim 1  wherein said excess glucocorticoids are the result of the long term administration of glucocorticoids to said individual. 
   
   
       5 . A method according to  claim 4 , wherein said administered glucocorticoid is dexamethasone. 
   
   
       6 . A method according to  claim 1 , wherein said glucocorticoid induced catabolic effects are selected from the group consisting of reduction in growth, reduction in growth rate, reduction in body weight, reduction in lean body mass, reduction in IGF-1 levels and reduction in bone mass. 
   
   
       7 . A method according to  claim 6 , wherein said amelioration alleviates the reduction in growth in an individual with excess glucocorticoids. 
   
   
       8 . A method according to  claim 7 , wherein said individual is a child. 
   
   
       9 . A method according to  claim 7 , wherein said individual is an adult. 
   
   
       10 . A method according to  claim 6 , wherein said amelioration alleviates the reduction in growth rate in an individual with excess glucocorticoids. 
   
   
       11 . A method according to  claim 7 , wherein said individual is a child. 
   
   
       12 . A method according to  claim 7 , wherein said individual is an adult. 
   
   
       13 . A method according to  claim 6 , wherein said amelioration alleviates the reduction in body weight in said individual with excess glucocorticoids. 
   
   
       14 . A method according to  claim 13 , wherein said individual is a child. 
   
   
       15 . A method according to  claim 13 , wherein said individual is an adult. 
   
   
       16 . A method according to  claim 6 , wherein said reduction in body weight is due in part to a reduction in the loss in lean body mass. 
   
   
       17 . A method according to  claim 16 , wherein said individual is a child. 
   
   
       18 . A method according to  claim 16 , wherein said individual is an adult. 
   
   
       19 . A method according to  claim 6 , wherein said amelioration alleviates the reduction in IGF-1 levels in said individual with excess glucocorticoids. 
   
   
       20 . A method according to  claim 19 , wherein said individual is a child. 
   
   
       21 . A method according to  claim 19 , wherein said individual is an adult. 
   
   
       22 . A method according to  claim 6 , wherein said amelioration alleviates the reduction in bone loss in said individual with excess glucocorticoids. 
   
   
       23 . A method according to  claim 22 , wherein said individual is a child. 
   
   
       24 . A method according to  claim 22 , wherein said individual is an adult. 
   
   
       25 . A method according to  claim 6  wherein said ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2  (SEQ ID NO:2). 
   
   
       26 . A method according to  claim 6  wherein said excess glucocorticoids result from the administration of dexamethasone. 
   
   
       27 . A method according to  claim 1 , wherein said administration is selected from the group consisting of intramuscular, intranasal, intraperitoneal, and intravenous administration. 
   
   
       28 . A method according to  claim 27 , wherein said administration is intramuscular administration. 
   
   
       29 . A method according to  claim 27 , wherein said administration is intranasal administration. 
   
   
       30 . A method according to  claim 27 , wherein said administration is intraperitoneal administration. 
   
   
       31 . A method according to  claim 27 , wherein said administration is intravenous administration. 
   
   
       32 . A method for allowing the long term administration of therapeutic doses of glucocorticoids to treat a disease or condition, comprising alleviating the catabolic effects of the administration of said long term therapeutic doses of glucocorticoids by the administration of a ghrelin agonist. 
   
   
       33 . A method according to  claim 32 , in which said ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2  (SEQ ID NO:2). 
   
   
       34 . A method according to  claim 32 , wherein said administered glucocorticoid is dexamethasone. 
   
   
       35 . A method according to  claim 32 , wherein said individual is a child. 
   
   
       36 . A method according to  claim 32 , wherein said individual is a child. 
   
   
       37 . A method according to  claim 32 , wherein said therapeutic amounts of glucocorticoids are administered to a child to treat respiratory distress of prematurity and said catabolic effects of said glucocorticoid treatment are alleviate by the administration of a ghrelin agonist. 
   
   
       38 . A method according to  claim 37 , in which said ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2  (SEQ ID NO:2). 
   
   
       39 . A method according to  claim 37 , wherein said exogenous glucocorticoid is dexamethasone. 
   
   
       40 . A method according to  claim 32 , wherein said therapeutic amounts of glucocorticoids are administered to an individual to treat asthma and said catabolic effects of said glucocorticoid treatment are alleviated by the administration of a ghrelin agonist. 
   
   
       41 . A method according to  claim 40 , in which said ghrelin agonist is [Aib 2 , Glu 3 (NH-hexyl)]hGhrelin(1-28)-NH 2  (SEQ ID NO:2). 
   
   
       42 . A method according to  claim 40 , wherein said exogenous glucocorticoid is dexamethasone. 
   
   
       43 . A method according to  claim 40 , wherein said individual is an adult. 
   
   
       44 . A method according to  claim 40 , wherein said individual is a child. 
   
   
       45 . A method according to  claim 32 , wherein said administration is selected from the group consisting of intramuscular, intranasal, intraperitoneal, and intravenous administration. 
   
   
       46 . A method according to  claim 32 , wherein said administration intramuscular administration. 
   
   
       47 . A method according to  claim 32 , wherein said administration is intranasal administration. 
   
   
       48 . A method according to  claim 32 , wherein said administration is intraperitoneal administration. 
   
   
       49 . A method according to  claim 32 , wherein said administration is intravenous administration.

Join the waitlist — get patent alerts

Track US2010227806A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.